Laurent Hocqueloux1, François Raffi2, Thierry Prazuck1, Louis Bernard3, Simon Sunder4, Jean-Luc Esnault5, David Rey6, Gwenaël Le Moal7, Mariam Roncato-Saberan8, Marie André9, Eric Billaud2, Antoine Valéry10, Véronique Avettand-Fènoël11, Jean-Jacques Parienti12, Clotilde Allavena2. 1. Service des Maladies Infectieuses et Tropicales, CHR d'Orléans-La Source, Tours. 2. Service des Maladies Infectieuses, CHU Hôtel Dieu and INSERM UIC 1413 Nantes University, Tours. 3. Service des Maladies Infectieuses, CHU Bretonneau, Tours. 4. Service des Maladies Infectieuses et Tropicales, CHG de Niort. 5. Service des Maladies Infectieuses, CHD de Vendée, La Roche-sur-Yon. 6. Le Trait d'Union, Hôpitaux Universitaires de Strasbourg. 7. Service des Maladies Infectieuses, CHU La Milétrie, Poitiers. 8. Service des Maladies Infectieuses, Groupe Hospitalier de La Rochelle-Ré-Aunis, Nancy. 9. Service des Maladies Infectieuses, CHRU-Brabois, Nancy. 10. Département d'Informatique Médicale, CHR d'Orléans-La Source, France. 11. Laboratoire de Microbiologie clinique, CHU Necker and Université Paris Descartes, Sorbonne Paris Cité. 12. Unité de Biostatistique et de Recherche Clinique, CHU de Caen; EA2656 Groupe de Recherche sur l'Adaptation Microbienne (GRAM 2.0), Université Caen Normandie, Caen, France.
Abstract
BACKGROUND: We investigated whether dolutegravir (DTG) monotherapy could be used to maintain virological suppression in people living with human immunodeficiency virus (HIV) on a successful dolutegravir-based triple therapy. METHODS: MONCAY (MONotherapy of TiviCAY) was a 48-week, multicentric, randomized, open-label, 12% noninferiority margin trial. Patients with CD4 nadir >100/μL, plasma HIV-1 RNA <50 copies/mL for ≥12 months, and stable regimen with DTG/abacavir (ABC)/lamivudine (3TC) were 1:1 randomized to continue their regimen or to DTG monotherapy. The primary endpoint was the proportion of patients with HIV RNA <50 copies/mL at week 24 in intention-to-treat snapshot analysis. Virologic failure (VF) was defined as 2 consecutive HIV RNA >50 copies/mL within 2 weeks apart. RESULTS:Seventy-eight patients were assigned to DTG monotherapy and 80 to continue DTG/ABC/3TC. By week 24, 2 patients in the DTG group experienced VF without resistance to the integrase strand transfer inhibitor (INSTI) class; 1 patient discontinued DTG/ABC/3TC due to an adverse event. The success rate at week 24 was 73/78 (93.6%) in the DTG arm and 77/80 (96.3%) in the DTG/ABC/3TC arm (difference, 2.7%; 95% confidence interval [CI], -5.0 to 10.8). During subsequent follow-up, 5 additional VFs occurred in the DTG arm (2 of which harbored emerging resistance mutation to INSTI). The cumulative incidence of VF at week 48 was 9.7% (95% CI, 2.8 to 16.6) in the DTG arm compared with 0% in the DTG/ABC/3TC arm (P = .005 by the log-rank test). The Data Safety Monitoring Board recommended to reintensify the DTG arm with standardized triple therapy. CONCLUSIONS: Because the risk of VF with resistance increases over time, we recommend avoiding DTG monotherapy as a maintenance strategy among people living with chronic HIV infection. CLINICAL TRIALS REGISTRATION: NCT02596334 and EudraCT 2015-002853-36.
RCT Entities:
BACKGROUND: We investigated whether dolutegravir (DTG) monotherapy could be used to maintain virological suppression in people living with human immunodeficiency virus (HIV) on a successful dolutegravir-based triple therapy. METHODS: MONCAY (MONotherapy of TiviCAY) was a 48-week, multicentric, randomized, open-label, 12% noninferiority margin trial. Patients with CD4 nadir >100/μL, plasma HIV-1 RNA <50 copies/mL for ≥12 months, and stable regimen with DTG/abacavir (ABC)/lamivudine (3TC) were 1:1 randomized to continue their regimen or to DTG monotherapy. The primary endpoint was the proportion of patients with HIV RNA <50 copies/mL at week 24 in intention-to-treat snapshot analysis. Virologic failure (VF) was defined as 2 consecutive HIV RNA >50 copies/mL within 2 weeks apart. RESULTS: Seventy-eight patients were assigned to DTG monotherapy and 80 to continue DTG/ABC/3TC. By week 24, 2 patients in the DTG group experienced VF without resistance to the integrase strand transfer inhibitor (INSTI) class; 1 patient discontinued DTG/ABC/3TC due to an adverse event. The success rate at week 24 was 73/78 (93.6%) in the DTG arm and 77/80 (96.3%) in the DTG/ABC/3TC arm (difference, 2.7%; 95% confidence interval [CI], -5.0 to 10.8). During subsequent follow-up, 5 additional VFs occurred in the DTG arm (2 of which harbored emerging resistance mutation to INSTI). The cumulative incidence of VF at week 48 was 9.7% (95% CI, 2.8 to 16.6) in the DTG arm compared with 0% in the DTG/ABC/3TC arm (P = .005 by the log-rank test). The Data Safety Monitoring Board recommended to reintensify the DTG arm with standardized triple therapy. CONCLUSIONS: Because the risk of VF with resistance increases over time, we recommend avoiding DTG monotherapy as a maintenance strategy among people living with chronic HIV infection. CLINICAL TRIALS REGISTRATION: NCT02596334 and EudraCT 2015-002853-36.
Authors: Matthew L Romo; Jessie K Edwards; Aggrey S Semeere; Beverly S Musick; Mark Urassa; Francesca Odhiambo; Lameck Diero; Charles Kasozi; Gad Murenzi; Patricia Lelo; Katarzyna Wyka; Elizabeth A Kelvin; Annette H Sohn; Kara K Wools-Kaloustian; Denis Nash Journal: Clin Infect Dis Date: 2022-09-10 Impact factor: 20.999
Authors: Ankur Gupta-Wright; Katherine Fielding; Joep J van Oosterhout; Melanie Alufandika; Daniel J Grint; Elizabeth Chimbayo; Judith Heaney; Matthew Byott; Eleni Nastouli; Henry C Mwandumba; Elizabeth L Corbett; Ravindra K Gupta Journal: Lancet HIV Date: 2020-09 Impact factor: 12.767
Authors: Nuttada Panpradist; Ingrid A Beck; Parker S Ruth; Santiago Ávila-Ríos; Claudia García-Morales; Maribel Soto-Nava; Daniela Tapia-Trejo; Margarita Matías-Florentino; Hector E Paz-Juarez; Silvia Del Arenal-Sanchez; Gustavo Reyes-Terán; Barry R Lutz; Lisa M Frenkel Journal: AIDS Date: 2020-07-15 Impact factor: 4.177
Authors: Andrew N Phillips; Francois Venter; Diane Havlir; Anton Pozniak; Daniel Kuritzkes; Annemarie Wensing; Jens D Lundgren; Andrea De Luca; Deenan Pillay; John Mellors; Valentina Cambiano; Loveleen Bansi-Matharu; Fumiyo Nakagawa; Thokozani Kalua; Andreas Jahn; Tsitsi Apollo; Owen Mugurungi; Polly Clayden; Ravindra K Gupta; Ruanne Barnabas; Paul Revill; Jennifer Cohn; Silvia Bertagnolio; Alexandra Calmy Journal: Lancet HIV Date: 2018-11-29 Impact factor: 12.767